Degludec outperforms glargine in curbing nocturnal hypoglycemia

05/6/2013 | Healio

Type 1 diabetes patients who received high-dose insulin degludec once daily showed lower rates of nocturnal hypoglycemia than their counterparts who took insulin glargine, a study showed. The findings were presented at the American Association of Clinical Endocrinologists annual meeting.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD